Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (61-70 of 323) with videos related to

Pageof 33
Sort By:
Therapeutic Advances in Medical Oncology|December 31, 2025
First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinomaSilvia Marchesi, Carolina Sciortino, Julian Etessami, et al.
Annals of Surgical Oncology|August 14, 2016
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal MetastasesDario Baratti, Shigeki Kusamura, Domenico Iusco, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 12, 2015
Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancerMaria Di Bartolomeo, Filippo Pietrantonio, Alessandro Pellegrinelli, et al.
World Journal of Clinical Cases|December 18, 2014
Role of MGMT as biomarker in colorectal cancerAlessandro Inno, Giuseppe Fanetti, Maria Di Bartolomeo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 2015
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II studyMaria Di Bartolomeo, Andrea Ciarlo, Alessandro Bertolini, et al.
ESMO Open|November 15, 2018
Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM)Maria Vittoria Dieci, Francesco Massari, Raffaele Giusti, et al.
International Journal of Colorectal Disease|March 29, 2020
A systematic review of salvage therapies in refractory metastatic colorectal cancerFausto Petrelli, Gianluca Perego, Antonio Ghidini, et al.
American Journal of Clinical Oncology|February 23, 2013
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II studyEmilio Bajetta, Filippo Pietrantonio, Roberto Buzzoni, et al.
Anticancer Research|April 9, 2013
A review on biomarkers for prediction of treatment outcome in gastric cancerFilippo Pietrantonio, Filippo De Braud, Valentina Da Prat, et al.
The Journal of Molecular Diagnostics : JMD|March 17, 2020
Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System ActivationRiccardo Giannini, Gemma Zucchelli, Mirella Giordano, et al.
Pageof 33

Showing results (61-70 of 323) with videos related to

Sort By:
Pageof 33
Therapeutic Advances in Medical Oncology|December 31, 2025
First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinomaSilvia Marchesi, Carolina Sciortino, Julian Etessami, et al.
Annals of Surgical Oncology|August 14, 2016
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal MetastasesDario Baratti, Shigeki Kusamura, Domenico Iusco, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 12, 2015
Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancerMaria Di Bartolomeo, Filippo Pietrantonio, Alessandro Pellegrinelli, et al.
World Journal of Clinical Cases|December 18, 2014
Role of MGMT as biomarker in colorectal cancerAlessandro Inno, Giuseppe Fanetti, Maria Di Bartolomeo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 2015
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II studyMaria Di Bartolomeo, Andrea Ciarlo, Alessandro Bertolini, et al.
ESMO Open|November 15, 2018
Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM)Maria Vittoria Dieci, Francesco Massari, Raffaele Giusti, et al.
International Journal of Colorectal Disease|March 29, 2020
A systematic review of salvage therapies in refractory metastatic colorectal cancerFausto Petrelli, Gianluca Perego, Antonio Ghidini, et al.
American Journal of Clinical Oncology|February 23, 2013
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II studyEmilio Bajetta, Filippo Pietrantonio, Roberto Buzzoni, et al.
Anticancer Research|April 9, 2013
A review on biomarkers for prediction of treatment outcome in gastric cancerFilippo Pietrantonio, Filippo De Braud, Valentina Da Prat, et al.
The Journal of Molecular Diagnostics : JMD|March 17, 2020
Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System ActivationRiccardo Giannini, Gemma Zucchelli, Mirella Giordano, et al.
Pageof 33